Clinical trial
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
NCT00230321 · Peter L Greenberg, Other · Completed
Key facts
| NCT number | NCT00230321 |
|---|---|
| Title | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) |
| Official title | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Peter L Greenberg, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Blood Cancer, Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS) |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa |
| Enrollment | 21 |
| Start date | Feb 1, 2002 |
| Primary completion | Nov 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Sep 30, 2005 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: